Nicola Heffron - 2Seventy Bio Chief Officer
| TSVT Stock | USD 2.69 0.13 4.61% |
Insider
Nicola Heffron is Chief Officer of 2Seventy Bio
| Age | 51 |
| Address | 60 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 675 7270 |
| Web | https://www.2seventybio.com |
Nicola Heffron Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nicola Heffron against 2Seventy Bio stock is an integral part of due diligence when investing in 2Seventy Bio. Nicola Heffron insider activity provides valuable insight into whether 2Seventy Bio is net buyers or sellers over its current business cycle. Note, 2Seventy Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell 2Seventy Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nicola Heffron over a year ago Sale by Nicola Heffron of tradable shares of 2Seventy Bio |
2Seventy Bio Management Efficiency
The company has return on total asset (ROA) of (0.1902) % which means that it has lost $0.1902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5189) %, meaning that it created substantial loss on money invested by shareholders. 2Seventy Bio's management efficiency ratios could be used to measure how well 2Seventy Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2025. Return On Capital Employed is likely to drop to -0.4 in 2025. Total Current Liabilities is likely to gain to about 66.8 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 574.1 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tom Harris | Phathom Pharmaceuticals | N/A | |
| MA MBA | Relay Therapeutics | 48 | |
| Mark Murcko | Relay Therapeutics | 65 | |
| Isabel Aznarez | Stoke Therapeutics | 53 | |
| Ronald Evans | Syndax Pharmaceuticals | 76 | |
| Carolyn Tang | Arcus Biosciences | 41 | |
| Ryan Brown | Sarepta Therapeutics | 46 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Jason Barker | Arcus Biosciences | 49 | |
| Noreen MD | Kezar Life Sciences | 59 | |
| Birgitte MD | Ascendis Pharma AS | 62 | |
| Alvin Pharmd | Puma Biotechnology | 71 | |
| Aditya Kohli | Phathom Pharmaceuticals | 37 | |
| Robert II | Arcus Biosciences | 52 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Keith CPA | Syndax Pharmaceuticals | 54 | |
| Christopher Garcia | Arcus Biosciences | N/A | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| JeanMarc MBA | Iovance Biotherapeutics | 53 | |
| David Socks | Phathom Pharmaceuticals | 50 | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.19 |
2Seventy Bio Leadership Team
Elected by the shareholders, the 2Seventy Bio's board of directors comprises two types of representatives: 2Seventy Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 2Seventy. The board's role is to monitor 2Seventy Bio's management team and ensure that shareholders' interests are well served. 2Seventy Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 2Seventy Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan AbuAbsi, Chief Officer | ||
| Teresa JD, General VP | ||
| Nick Leschly, President Director | ||
| DPHIL Phil, Chief Officer | ||
| Anna TruppelHartmann, Chief Officer | ||
| Victoria Eatwell, Chief Officer | ||
| Steven Shamah, Head Research | ||
| MS MD, Head Devel | ||
| Jessica Snow, Senior Operations | ||
| Anna MD, Chief Officer | ||
| Nicola Heffron, Chief Officer | ||
| William III, Chief Officer | ||
| Jenn Snyder, Senior Affairs | ||
| MBA III, Principal Officer | ||
| Steven MD, Chief Officer | ||
| Kathleen Wilkinson, Head Culture | ||
| Kerri Jensen, Head Culture | ||
| Vicki Eatwell, Chief Officer | ||
| Michael Certo, VP Editing |
2Seventy Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 2Seventy Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (2.07) % | ||||
| Operating Margin | (0.99) % | ||||
| Current Valuation | 200.53 M | ||||
| Shares Outstanding | 51.59 M | ||||
| Shares Owned By Insiders | 4.04 % | ||||
| Shares Owned By Institutions | 90.40 % | ||||
| Number Of Shares Shorted | 4.68 M | ||||
| Price To Book | 0.64 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.